AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ECO ANIMAL HEALTH GROUP PLC

Regulatory Filings Apr 2, 2019

7612_rns_2019-04-02_dd0620d8-176f-4d0e-bb3e-c77efe42ae64.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

Regulatory Approval

2 April 2019

ECO Animal Health Group plc

(AIM: EAH)

ECO RECEIVES EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR BREEDING CHICKENS

ECO Animal Health Group plc (the “Group”) is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) in breeding chickens.

This approval allows ECO to market Aivlosin® 625 mg/g WSG in Europe for the treatment and metaphylaxis of respiratory infections caused by Mycoplasma gallisepticum in breeding chickens producing eggs, for hatching broiler stock and for replacement layers.

Aivlosin®, ECO’s patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

Marc Loomes, CEO, commented: “The EU has five per cent of the world’s layer and ten per cent of the world’s broiler parent stock. This marketing authorisation is very significant as it provides an opportunity to roll out the approval beyond the EU into the multi-million dollar large international poultry markets. This will enable ECO to capitalise on the considerable global potential for Aivlosin® which offers a safe and highly effective medication for Mycoplasma infections in high value breeding birds”.

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc

Marc Loomes 020 8447 6906
Spiro Financial
Anthony Spiro 020 8336 6196
IFC Advisory Ltd

Graham Herring, Miles Nolan
0203 934 6630
N+1 Singer (Nominated Adviser and Joint Broker) 020 7496 3000
Mark Taylor, James White, Brough Ransom
Peel Hunt LLP (Joint Broker)
James Steel, Dr Christopher Golden 020 7418 8900

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

Eco Animal Health Group Plc

View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005683/en/

Talk to a Data Expert

Have a question? We'll get back to you promptly.